Edit and publish insight
Signal headline
Decision / action required
Owner → function
Deadline
Priority
Action
QC workflow: Draft → Under QC review (team notified) → Published. AI-generated insights are always saved as draft first. Use "Send for QC review" to flag for team sign-off before publishing.
Change detail
Add market
1
Welcome
Platform tour
Good morning
Here's what you need to know across your NITAG portfolio today.
This week at a glance
—
Total signals
—
High priority (urgent + watch)
—
Therapy areas tracked
Loading…
Signal
Market
Identity
Set your email
Used to attribute actions you take and assignments you receive. Saved to this browser only.
This identity is used to mark who actioned or assigned each item. Stored locally in your browser; not shared with other users.
Action
—
—
6 updates require action this week
2 urgent (US RSV revenue model + Germany BIA). 2 watch (UK COVID-19 contraction, France flu evidence bar). 2 positive (NACI CDI expansion, Japan RSV opportunity). Use the toggles to assign, mark actioned, or filter to your own assignments.
2
Urgent
2
Watch
2
Positive
9
Markets
Updates Requiring Action This Week
What You Need To Do
Asset-specific actions this week
Decision Timeline
Upcoming inflection points across all markets
| Market | Therapy area | Body | Cohort (as defined by NITAG committee) | Current recommendation | Revaccination schedule (= forecast commercial impact) | Next meeting / decision | Source |
|---|
Agenda confirmed
Agenda pending
Past
Use this view to understand each NITAG body's decision style. Some bodies favour close split votes (ACIP); others operate by consensus (JCVI, STIKO). Some lead globally (ACIP, NACI on AMR); others follow within 6–12 months (JCVI, AIFA, CISNS). Knowing the pattern helps anticipate what's coming and where AZ can engage. Entries marked illustrative follow the pattern from the source notes but aren't confirmed vote tallies.
Quick prompts
Active scan sources
Health security, AMR & specialist media sources
Non-NITAG sources for AMR guidance, specialist regulatory media, and disease surveillance. Toggle on/off individually. Click the external link icon to verify the URL is live before activating scan.
Other public sources
Specialist pharmaceutical trade press and peer-reviewed vaccine intelligence. Filtered to platform scope (NITAG decisions, immunization recommendations, regulatory and HTA actions, AMR signals). Irrelevant general-news items are excluded.
Therapy areas in scope
Scan schedule
Frequency
Video ingestionYouTube and stream transcripts enabled
LanguagesEN · DE · FR · IT · ES · JA · ZH
TranslationMachine + human QA
Last scan4 May 2026 09:41 — 6 new items
Active scan coverage
Loading…